• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 4. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 5. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidinethiones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidinethiones
• Solvents and Organic Chemicals Organic Compounds cyanides/Cyanides

4-(Trifluoromethyl)pyrimidine-2-thiol (CAS No. 136547-17-6): A Comprehensive Overview

4-(Trifluoromethyl)pyrimidine-2-thiol (CAS No. 136547-17-6) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique trifluoromethyl and thiol functionalities, exhibits a wide range of biological activities and has been the subject of numerous studies aimed at elucidating its potential therapeutic applications.

The chemical structure of 4-(Trifluoromethyl)pyrimidine-2-thiol consists of a pyrimidine ring with a trifluoromethyl group at the 4-position and a thiol group at the 2-position. The trifluoromethyl group imparts unique electronic and steric properties to the molecule, which can significantly influence its reactivity and biological activity. The thiol group, on the other hand, is known for its nucleophilic and redox properties, making it an important functional group in various biochemical processes.

Recent advancements in synthetic methodologies have facilitated the efficient synthesis of 4-(Trifluoromethyl)pyrimidine-2-thiol. One notable approach involves the reaction of 2-chloro-4-(trifluoromethyl)pyrimidine with sodium hydrosulfide, yielding the desired product in good yields. This synthetic route has been optimized to minimize side reactions and improve overall efficiency, making it suitable for large-scale production.

In terms of biological activity, 4-(Trifluoromethyl)pyrimidine-2-thiol has shown promising results in various assays. Studies have demonstrated its potential as an inhibitor of specific enzymes involved in cancer cell proliferation. For instance, it has been reported to inhibit the activity of thioredoxin reductase, an enzyme that plays a crucial role in maintaining cellular redox balance and protecting cells from oxidative stress. By targeting this enzyme, 4-(Trifluoromethyl)pyrimidine-2-thiol can potentially disrupt the survival mechanisms of cancer cells, leading to their apoptosis.

Beyond its anti-cancer properties, 4-(Trifluoromethyl)pyrimidine-2-thiol has also been investigated for its potential as an antimicrobial agent. Research has shown that it exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria. The thiol group is believed to play a key role in this activity by interacting with bacterial cell wall components and disrupting their integrity. This makes 4-(Trifluoromethyl)pyrimidine-2-thiol a promising candidate for the development of new antibiotics to combat multidrug-resistant bacterial strains.

The pharmacokinetic properties of 4-(Trifluoromethyl)pyrimidine-2-thiol have also been studied extensively. In vitro and in vivo experiments have demonstrated that it exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. These properties are crucial for ensuring that the compound can effectively reach its target site within the body and exert its intended therapeutic effects without causing significant toxicity.

Clinical trials are currently underway to evaluate the safety and efficacy of 4-(Trifluoromethyl)pyrimidine-2-thiol in various therapeutic settings. Preliminary results from phase I trials have shown that it is well-tolerated by patients at therapeutic doses, with no major adverse effects reported. These findings are encouraging and suggest that further clinical development is warranted.

In conclusion, 4-(Trifluoromethyl)pyrimidine-2-thiol (CAS No. 136547-17-6) is a multifaceted compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique chemical structure confers a range of biological activities, making it a valuable lead compound for the development of new therapeutic agents. Ongoing research continues to uncover new applications and optimize its properties, paving the way for future breakthroughs in drug discovery and development.

• 62772-93-4(2-(methylsulfanyl)-4,6-bis(trifluoromethyl)pyrimidine)
• 62772-91-2(Pyrimidine, 4-methyl-2-(methylthio)-6-(trifluoromethyl)-)
• 136547-20-1(2-methylsulfanyl-4-(trifluoromethyl)pyrimidine)
• 502927-05-1(PYRIMIDINE, 4-(BROMOMETHYL)-2-(METHYLTHIO)-6-(TRIFLUOROMETHYL)-)
• 136547-16-5(4-(Trifluoromethyl)pyrimidine)
• 13654-17-6(4-(TRIFLUOROMETHYL)PYRIMIDINE-2-THIOL)
• 871592-25-5(PYRIMIDINE, 4-ETHENYL-2-(METHYLTHIO)-6-(TRIFLUOROMETHYL)-)
• 62772-92-3(Pyrimidine, 4-ethyl-2-(methylthio)-6-(trifluoromethyl)-)
• 146547-33-3(Acetonitrile, [[4-methyl-6-(trifluoromethyl)-2-pyrimidinyl]thio]-)
• 149771-18-6(2-Methyl-4-(trifluoromethyl)pyrimidine)